21 – 30 of 157
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
(
- Contribution to journal › Letter
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article